Lulu Sun

Lulu Sun

Auto-generated profile, based on publicly available information

Lulu Sun

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
LSLulu Sun
Lulu Sun
JCJie Cai
Jie Cai
FGFrank Gonzalez
Frank Gonzalez

19 October 2022 in Nature
Verified
Journal Article
Closed access
PDF file
BCBo Chen
Bo Chen
LSLulu Sun
Lulu Sun
GZGuangyi Zeng
Guangyi Zeng
ZSZhe Shen
Zhe Shen
KWKai Wang
Kai Wang
CJChangtao Jiang
Changtao Jiang

10 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LSLulu Sun
Lulu Sun
YZYi Zhang
Yi Zhang
JCJie Cai
Jie Cai
BRBipin Rimal
Bipin Rimal
EREdson R. Rocha
Edson R. Rocha
FGFrank Gonzalez
Frank Gonzalez
Bile salt hydrolase (BSH) in Bacteroides is considered a potential drug target for obesity-related metabolic diseases, but its involvement in colon tumorigenesis has not been explored. BSH-expressing Bacteroides is found at high abundance in the stools of colorectal cancer (CRC) patients with overweight and in the feces of a high-fat diet (HFD)-induced CRC mouse model. Colonization of B. fragilis 638R, a strain with low BSH activity, overexpressing a recombinant bsh gene from B. fragilis NCTC9343 strain, results in increased unconjugated bile acids in the colon and accelerated progression of CRC under HFD treatment. In the presence of high BSH activity, the resultant elevation of unconjugated deoxycholic acid and lithocholic acid activates the G-protein-coupled bile acid receptor, resulting in increased β-catenin-regulated chemokine (C-C motif) ligand 28 (CCL28) expression in colon tumors. Activation of the β-catenin/CCL28 axis leads to elevated intra-tumoral immunosuppressive CD25+FOXP3+ Treg cells. Blockade of the β-catenin/CCL28 axis releases the immunosuppression to enhance the intra-tumoral anti-tumor response, which decreases CRC progression under HFD treatment. Pharmacological inhibition of BSH reduces HFD-accelerated CRC progression, coincident with suppression of the β-catenin/CCL28 pathway. These findings provide insights into the pro-carcinogenetic role of Bacteroides in obesity-related CRC progression and characterize BSH as a potential target for CRC prevention and treatment.

1 July 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
YLYuhong Luo
Yuhong Luo
SYShoumei Yang
Shoumei Yang
XWXuan Wu
Xuan Wu
STShogo Takahashi
Shogo Takahashi
LSLulu Sun
Lulu Sun
FGFrank Gonzalez
Frank Gonzalez

8 September 2018 in Acta Biochimica Polonica
Verified
Journal Article
Open access
EKElena Kazakova
Elena Kazakova
MCMeijun Chen
Meijun Chen
EJEsma Jamaspishvili
Esma Jamaspishvili
ZLZhang Lin
Zhang Lin
JYJingling Yu
Jingling Yu
HQHong Qiao
Hong Qiao
Two recent studies found that RBMS1 gene rs7593730 and BCAR1 gene rs7202877 had relationships with type 2 diabetes. However, the association of these loci with type 2 diabetes mellitus (T2DM) has not been examined in Chinese. We performed a replication study to investigate the association of 2 susceptibility loci with T2DM in the Chinese population. We genotyped 1961 Chinese participants (991 with T2DM and 970controls) for each of the 2 single nucleotide polymorphisms (SNPs) rs7593730 in RBMS1 and rs7202877 near BCAR1 using SNPscan and examined the association of them with T2DM using logistic regression analysis. We also analyzed the correlation of the SNP allele and clinical phenotypes. In additive model, genotype association analysis of BCAR1 rs7202877 loci revealed that the homozygous of rs7202877 GG carriers had a significant decreased T2DM risk compared to homozygous carriers of TT (p= 0.038, OR 0.44, 95 % CI 0.20-0.96). In the recessive model, the genotype GG carriers had a significant decreased T2DM risk compared to GT+TT (p= 0.043, OR 0.67, 95% CI 0.46-0.99). Allele G was statistically significantly correlated with TC (mmol/L) (P=0.036) and LDL-C (mmol/L) (P=0.007). As for rs7593730, the carriers of genotype CT and TT had significantly decreased T2DM risk compared with the carriers of genotype CC (CT: CC P=0.038, OR 0.71, 95%CI 0.51-0.98; TT: CC P=0.010, OR 0.32, 95%CI 0.13-0.76). In a dominant model, TT+CT: CC (p= 0.013, OR 0.673, 95 % CI 0.49-0.92) and in a recessive model, TT: CT+CC (p= 0.019, OR 0.59, 95% CI 0.39-0.92). The T allele carriers had a significant decreased T2DM risk compared to carriers of C (p= 0.002, OR 0.65, 95 % CI 0.50-0.86). Allele T was statistically correlated with FINS (P=0.010). In conclusion, our study showed that RBMS1 gene rs7593730 and BCAR1 gene rs7202877 were significantly associated with type 2 diabetes in the Chinese population.

24 November 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
YCYaozong Chen
Yaozong Chen
LSLulu Sun
Lulu Sun
IUIrfan Ullah
Irfan Ullah
GBGuillaume Beaudoin-Bussières
Guillaume Beaudoin-Bussières
SASai Priya Anand
Sai Priya Anand
MPMarzena Pazgier
Marzena Pazgier
Soluble Angiotensin-Converting Enzyme 2 (ACE2) constitutes an attractive antiviral capable of targeting a wide range of coronaviruses utilizing ACE2 as their receptor. Here, using structure-guided approaches, we developed divalent ACE2 molecules by grafting the extracellular ACE2-domain onto a human IgG1 or IgG3 (ACE2-Fc). These ACE2-Fcs harbor structurally validated mutations that enhance spike (S) binding and remove angiotensin enzymatic activity. The lead variant bound tightly to S, mediated in vitro neutralization of SARS-CoV-2 variants of concern (VOCs) with sub-nanomolar IC 50 and was capable of robust Fc-effector functions, including antibody-dependent-cellular cytotoxicity, phagocytosis and complement deposition. When tested in a stringent K18-hACE2 mouse model, it delayed death or effectively resolved lethal SARS-CoV-2 infection in a prophylactic or therapeutic setting utilizing the combined effect of neutralization and Fc-effector functions. These data confirm the utility of ACE2-Fcs as valuable agents in preventing and eliminating SARS-CoV-2 infection and demonstrate that ACE2-Fc therapeutic activity require Fc-effector functions.